ArticleFrontiers in oncology2026
Case Report: A successfully managed case of SMARCA4-deficient undifferentiated gastric carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of SMARCA4-deficient poorly-to-undifferentiated gastric carcinoma. The patient underwent surgical resection. Postoperative treatment combined chemotherapy, immunotherapy, and targeted therapy. The regimen included ifosfamide, liposomal doxorubicin hydrochloride, cadonilimab, and anlotinib capsules. Follow-up to date shows no tumor recurrence or metastasis. The postoperative relapse-free survival (RFS) has now reached 33 months. Primary gastric SMARCA4-deficient undifferentiated tumors carry a poor prognosis, with survival typically under one year. Here we present a successfully treated case of this tumor type originating in the stomach. This case may serve as a reference for future management of such tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.